U.S. markets close in 3 hours 32 minutes

Ekso Bionics Holdings, Inc. (EKSO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.0800-0.1300 (-4.05%)
As of 12:21PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close3.2100
Bid3.0300 x 2200
Ask3.0400 x 1200
Day's Range3.0200 - 3.2300
52 Week Range3.0200 - 14.9800
Avg. Volume124,761
Market Cap39.004M
Beta (5Y Monthly)1.92
PE Ratio (TTM)N/A
EPS (TTM)-1.0110
Earnings DateFeb 23, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for EKSO

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Ekso Bionics Holdings, Inc.
    Analyst Report: Zimmer Biomet Holdings, Inc.Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Close to 60% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products; the remaining portion is primarily related to spine and dental products.
    Fair Value
    Economic Moat
    6 days agoMorningstar
View more
  • Zacks

    Ekso Bionics (EKSO) Reports Q3 Loss, Tops Revenue Estimates

    Ekso Bionics (EKSO) delivered earnings and revenue surprises of 32.00% and 18.18%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Ekso Bionics Reports Third Quarter 2021 Results

    RICHMOND, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended September 30, 2021. Recent Highlights and Accomplishments Reported revenue of $3.0 million in the third quarter of 2021Achieved gross margin of approximately 59% in the third quarter of 2021Booked a total of 16 EksoNR units in the third quarter of 202

  • GlobeNewswire

    Ekso Bionics to Report Third Quarter 2021 Financial Results on November 2, 2021

    RICHMOND, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the third quarter 2021 after the close of trading on Tuesday, November 2, 2021. Management will host a conference call beginning at 1:30 p.m. PT, 4:30 p.m. ET to discuss the financial results and recent business developments. A live webcas